GlassScriptPhysician profile
Marian H Smith
NPI 1215426036
$1,442.99
in general payments reported to CMS, 2019-2025
15 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $313 · 2023: $184 · 2024: $196 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $236.69 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $234.06 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $223.09 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $160.75 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $153.98 | 2021-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $124.44 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.41 | 2021-2025 | Jardiance |
| Abbvie INC. | $37.72 | 2022-2024 | |
| Dexcom, INC. | $33.84 | 2023-2025 | Dexcom G6 Transmitter |
| Cumberland Pharmaceuticals, INC. | $33.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.45 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $24.22 | 2024 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $23.44 | 2023 | Keveyis |
| Ascensia Diabetes Care US INC. | $17.27 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.